candesartan has been researched along with benzofurans in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bell, PD; Peti-Peterdi, J; Warnock, DG | 1 |
Alonso-Galicia, M; Corona, A; Felix, JP; Garcia, ML; Gill, C; Hampton, C; Kaczorowski, GJ; Kohler, M; Liu, J; Metzger, JM; Ormes, J; Owens, K; Pai, LY; Pasternak, A; Price, O; Priest, BT; Rasa, C; Roy, S; Shah, K; Sullivan, KA; Tang, H; Thomas-Fowlkes, B; Tong, V; Xiao, J; Zhou, X | 1 |
2 other study(ies) available for candesartan and benzofurans
Article | Year |
---|---|
Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors.
Topics: Amiloride; Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Benzofurans; Biphenyl Compounds; Hydrogen-Ion Concentration; Intracellular Membranes; Ionophores; Kidney Tubules, Collecting; Losartan; Mice; Microscopy, Fluorescence; Monensin; Rabbits; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Signal Transduction; Sodium Chloride; Tetrazoles | 2002 |
The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II Phenotype.
Topics: Animals; Bartter Syndrome; Benzimidazoles; Benzofurans; Biphenyl Compounds; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Female; HEK293 Cells; Humans; Hydrochlorothiazide; Male; Phenotype; Piperazines; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Rats; Tetrazoles | 2016 |